In humans, a successful therapeutic approach that focuses on designing specific inhibitors of FAP to overcome the FGF21-resistant state associated with obesity and type 2 diabetes would succeed. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.